INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

General Current Perspectives on All Hepatitis Viruses- A Comprehensive Review

Sakshi Shinde*, Ankita Darekar, Dr. Ashok Giri

Pharmacy practice department,Shivlingeshwar college of pharmacy, Almala, Dist. Latur 413512

ARTICLE INFO

Published: 03 Mar 2026
Keywords:
Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E.
DOI:
10.5281/zenodo.18851058

ABSTRACT

Every hepatitis virus—Hepatitis A, B, C, D, E, and G—presents a unique situation for both patients and medical professionals. Since each virus was discovered, a great deal of information about virologic characteristics, epidemiology, and the natural clinical and immunologic history of acute and chronic infections has been produced. Hepatitis A, B, and E vaccines and very effective antivirals for Hepatitis B and C have been developed as a result of basic insights concerning host immunologic responses to acute and chronic viral infections and virologic data. Hepatology, transplant medicine generally, and public and international health are all being revolutionized by these therapeutic advances. Most notably, an ambitious global effort is underway to eradicate chronic viral hepatitis within the next ten years [(1)]. Although achievable, there are numerous obstacles to this objective that are being actively researched at the local, national, and worldwide levels in both basic and clinical labs. For each of the distinct hepatitis viruses, we address relevant clinical data and current organizational guidelines here. We also synthesize this data with the most recent research to highlight promising future possibilities for each virus[1]. Humanity has been greatly impacted by viral infections of the liver, which have caused considerable morbidity and mortality in both acute and chronic infection patients. The scientific world became interested in determining the pathogenesis and diagnostic techniques to identify the afflicted population after the discovery of the viral agents, which had previously been an unknown aetiology. Rapid advancements in science and technology over the past few centuries have made it possible to treat and even cure illnesses, with a major emphasis on preventative care through vaccination. In order to treat these patients, primary care doctors and gastroenterologists must have a thorough awareness of hepatitis A, B, C, D, and E. With an emphasis on future treatment possibilities and the function of liver transplantation, the review paper explains the epidemiology, pathophysiology, clinical presentation, diagnostic tools, and existing pharmaceutical regimens (2). Hepatitis B and C viruses are a worldwide health concern that

***Corresponding Author:** Sakshi Shinde
Address: *Pharmacy practice department,Shivlingeshwar college of pharmacy, Almala, Dist. Latur 413512*
Email ✉: smshindeapur@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

can cause both acute and chronic infections that can result in hepatocellular carcinoma (HCC) and liver cirrhosis. These infections are the primary cause of HCC globally and are linked to a high death rate—more than 1.3 million fatalities annually. HCC accounts for around 90% of all occurrences of primary liver cancer, which is the second most common cause of cancer-related death globally due to its high prevalence and treatment resistance. Although hepatitis B virus infection can cause HCC development without preceding end-stage liver disease, the majority of viral-associated HCC cases occur in individuals with liver cirrhosis [3]. In India, where HAV and HEV are hyperendemic, viral hepatitis is a serious public health concern. 90% to 100% of people develop anti-HAV antibodies and become immune by adolescence, according to seroprevalence studies. With a carrier frequency of 2%–4%, HBV endemicity in India is intermediate. In India, horizontal transmission causes chronic HBV infection in children, most likely before the age of five. The prevalence of HCV infection in India is approximately 1%, and it is mostly caused by transfusions and the use of non-sterile glass syringes. Between 60% and 80% of people have HCV genotypes 3 and 2, which react favorably to an interferon and ribavirin combination. In India, 10%–15% of CLD and HCC cases are linked to HCV infection. Post-transfusion hepatitis is also frequently caused by HCV infection. In India, HDV infection is rare and affects 5%–10% of patients with liver disease caused by HBV [4].

INTRODUCTION

Since Hippocrates described comparable jaundice in the fifth century BC on the island of thassos, viral hepatitis has been a tough problem that has caused epidemics since ancient times. Outbreaks of the disease have been documented as early as 5000 years ago in China. The identification of the viruses was made possible by technological developments in the modern era, and further scientific investigation transformed the morbidity and death brought on by these viral infections. Our goal is to give a general overview of viral hepatitis and to cover both existing and potential treatments. Even if the majority are still prevalent in some regions of the world, globalization necessitates a basic awareness of each virus because we could all come across one on a regular basis [5,6]. Four of the five human hepatitis viruses—hepatitis types A, B, C, and D—have been found to be endemic in the United States. Hepatitis A accounts for 32% of the reported cases of acute viral hepatitis in this nation, followed by hepatitis B (43%) and hepatitis C (21%). Although delta hepatitis is not a condition that needs to be reported, it has been estimated that coinfection with the hepatitis delta virus (HDV) accounts for 4% of acute hepatitis B cases. An additional 4% of acute cases could be caused by a viral hepatitis agent or agents that are now categorized as non-ABCDE but have not yet been found. There are no reports of hepatitis E virus (HEV) transmission in the United States. Certain diagnostic tests are required to identify the etiologic agent in each patient because many of the clinical and epidemiologic characteristics of these different forms of hepatitis are identical [7]. Antiviral therapy's primary goal is to eradicate the virus, which is defined as a viral RNA that is undetectable by extremely sensitive techniques (lower detection limit of 15 IU/mL). If this RNA is still undetectable 12 weeks after stopping therapy, it is regarded as a sustained viral response (SVR) (SVR12). Pegylated interferon and ribavirin (PEG/RBV) for 24 or 48 weeks, depending on the genotype, was the sole available treatment option until a few years ago. The viral response rates, however, were only marginally higher in the other genotypes and did not exceed 50% in genotypes 1 and 4[9]. Nucleotide sequence comparisons and typing assays created from sequence data have become the primary methods for defining various HCV variants in the absence of a cell culture system to examine variations in neutralizing and cytopathic characteristics of HCV. Because viral sequences may be amplified directly from clinical specimens using the polymerase chain reaction (PCR), this kind of investigation is comparatively simple to carry out. HCV sequence comparisons have revealed details about the virus on a number of levels. HCV can be

recognized and categorized into a number of unique "genotypes," which exhibit different geographic and epidemiological distributions and differ significantly in nucleotide sequence from one another [10]. The two goals of hepatitis vaccinations are to lower the incidence of chronic liver disease and hepatocellular cancer as well as to prevent the morbidity and occasional fatality linked to acute hepatitis virus infection. Hepatitis A and B are the main preventive targets for the former goal, whereas hepatitis B and C are the main goals for the latter. Both hepatitis A and hepatitis B can be avoided by vaccination, despite the fact that several obstacles have hindered the development of hepatitis C vaccinations. Recently approved hepatitis A vaccines are traditional inactivated whole-virus vaccines made from virus cultured in cell culture, in contrast to more recent hepatitis B vaccines, which are subunit vaccinations made by recombinant DNA techniques. Although the structure and biology of HAV and HBV3,22 differ significantly between these opposing vaccine formulations, their immunogenicity and effectiveness are strikingly comparable [11]. There are now more options to manage HBV and HCV infections and possibly avoid liver disease consequences thanks to new medicines for both viruses [12]. Depending on the cause, acute hepatitis might result in fulminant liver failure even though it typically resolves on its own. On the other hand, chronic hepatitis can cause cirrhosis, hepatocellular cancer, liver fibrosis, and portal hypertension symptoms, all of which increase morbidity and death [13]. All structure of viral hepatitis Fig;1,



Fig1; Structure of hepatitis A, B, C, D, E viruses [8].

Types:

Hepatitis A:

Hepatitis A is a form of viral hepatitis, an infectious liver illness brought on by the Hepatitis A virus (HAV). Many cases, particularly in young people, show few or no symptoms. For individuals who experience symptoms, it takes two to six weeks between exposure and onset. The symptoms, which might include nausea, vomiting, diarrhea, jaundice, fever, and abdominal discomfort, usually linger for eight weeks. In the six months following the first infection, symptoms reoccur in about 10–15% of cases. Rarely, acute liver failure can happen; older people are more likely to experience it [14].

Etiology: One of the most frequent causes of acute hepatitis infection globally is HAV. An important step in understanding acute infectious hepatitis

was made in 1973 when immunological electron microscopy revealed a virus-like antigen, which ultimately led to the identification of HAV. HAV is currently recognized as the only member of the Hepatovirus genus within Picornaviridae, having formerly been classed as enterovirus type 72. Although HAV has evolutionary roots in bats, rats, and shrews and shares structural similarities with insect-infecting picornaviruses, it has unique hepatotropism and life cycle characteristics. This icosahedral, nonenveloped virus, which has a diameter of 27 to 32 nm, is spread fecal-orally and exhibits distinct physical changes when it is eliminated as opposed to circulating in the blood. Six genotypes—three of which infect humans and three of which are found in primates—are revealed by genomic analysis. Human infections are primarily caused by genotype 1, however genotype distribution varies geographically. An internal ribosome entrance site, altered capsid proteins, and particular replication elements are all present in the 7.5 kb positive-sense single-stranded ribonucleic acid that is the HAV genome [17].

Sign and Symptoms: The symptoms of a hepatitis A infection can vary greatly, from extremely minor to fairly severe. However, hepatitis A symptoms may not be present in many cases, especially in youngsters.

When symptoms do show up, they usually do so two to six weeks after the HAV exposure and can include:

Exhaustion Fever
decreased appetite
Sickness and vomiting
Pain in the abdomen, particularly near the liver
Dark urine (caused by incapacity to metabolize bilirubin or decreased bile flow)
White stools
Jaundice, or yellowing of the eyes and skin [20].

Pathophysiology:

Hepatocytes are infected with HAV through the HAV cellular receptor-1, also called the T-cell immunoglobulin mucin domain-1 receptor, in the Disse space. Recent research findings point to different access routes. The host's reaction to HAV infection involves a complicated interaction between innate and adaptive immune responses. In order to circumvent innate defense, HAV uses viral proteases that target important signaling molecules and inhibit the type I interferon response. However, because plasmacytoid dendritic cells generate large amounts of type I interferons in response to HAV-infected cells or eHAV, innate immunity is not totally circumvented. Hepatocellular damage may result from the adaptive immune response, especially T-cell-mediated immunity, which seems to be essential for viral clearance. Although virus-specific cytotoxic CD8 T cells have been found in human investigations, current findings in chimpanzee models point to a more significant involvement for CD4 helper T cells in the resolution of infection. The regulation of liver damage has also been linked to the dynamics of regulatory T cells during acute infection. Finding blood IgM antibodies to HAV or tracking seroconversion in symptomatic patients are the main methods used to diagnose acute hepatitis A. The sequestration of viral antigens causes delayed B-cell responses in humans and animals. Targeting conserved viral capsid protein epitopes, a quick, dominant, neutralizing IgG response offers long-lasting protection after infection. Liver illness can be prevented by passive immunization or postexposure vaccination within two weeks, most likely by post-endocytic neutralization of eHAV. Declining intrahepatic viral ribonucleic acid is correlated with multifunctional virus-specific CD4 T lymphocytes, suggesting that their main purpose is to regulate infection and interferon-stimulated genes [18].

Management:

Hepatitis A does not have a specific antiviral treatment. Rather, supportive care is the main emphasis of hepatitis A management in order to alleviate symptoms and guarantee proper diet and hydration. After an infection, recovery from symptoms may be sluggish and take weeks or months. Avoiding needless drugs that can harm the liver, such paracetamol and acetaminophen, is crucial. In the absence of abrupt liver failure or severe illness, hospitalization is not essential. The goal of therapy is to maintain comfort and a healthy nutritional balance, which includes replenishing lost fluids from diarrhea and vomiting [16]. Patients whose hepatic synthetic function is deteriorating need specific attention. Coagulopathy with a prolonged international normalized ratio, rising creatinine, serum albumin levels below 3%, rising blood ammonia levels, and clinical signs of hepatic encephalopathy are indicators of hepatic synthetic dysfunction that require immediate transfer to an intensive care unit, preferably at a liver transplant center. The United Network for Organ Sharing liver failure medical urgency classification (e.g., MELD 1 or PELD 2) or a status (e.g., 1A or 1B) for liver allocation based on national regulations and transplant facility accessibility should be used to categorize patients. Consequently, extrahepatic problems are treated. Based on anecdotal data and a small number of case reports, patients have received a brief course of corticosteroids in rare situations of severe recurrence and cholestatic symptoms; however, randomized controlled trials are inadequate [19].

Hepatitis B:

The Hepatitis B Virus (HBV), a deoxyribonucleic acid (DNA) virus that is a member of the Orthohepadnavirus genus and the Hepadnaviridae family, is the cause of hepatitis B. It is spread through contact with contaminated blood or body fluids, most frequently through sexual intercourse, intravenous drug use, or vertical transmission from mother to child. Due to vaccination, the burden of HBV is decreasing in the industrialized world; nevertheless, in endemic areas, the prevalence of HBV is still very high, mainly because of early life exposures and vertical transmission from mother to child. The primary determinant of the disease's progression is the age at which HBV infection occurs; most patients with perinatal infection go on to develop chronic hepatitis B, while most people with infection quickly get rid of the virus [15].

Etiology:

Sexual activity, injectable drug use, or occupational exposure are the main causes of HBV infections in developed nations. Hemodialysis, receiving organs or blood products, household contact, and transmission by a surgeon are additional, less common sources of infection [22].

Sign and Symptomes:

Jaundice, or yellowing of the skin and eyes, is a symptom of an acute disease that some people have for several weeks.
Dark urine
Extreme fatigue
Nausea
Vomiting
Abdominal discomfort [21].

Pathophysiology:

Although direct viral cytotoxicity can happen in severe infections, the majority of liver damage is immune-mediated: HBV antigens on infected cells cause cytotoxic T-cell responses, which result in hepatocyte lysis. Persistence or severity is influenced by viral variables such as genotypes, immune evasion, and mutants (such as core promoter alterations) [24].

Management:

Acute hepatitis B has no known cure. Antiviral drugs are a treatment option for chronic hepatitis B. The goal of treatment for those with acute hepatitis B should be to control symptoms. To avoid dehydration from vomiting and diarrhea, they should eat a nutritious meal and stay hydrated.Tenofovir and entecavir are two oral medications that can be used to treat chronic hepatitis B. Treatment can enhance long-term survival, halt the progression of cirrhosis, and lower the incidence of liver cancer.Treatment for hepatitis B must be continued for life for the majority of patients.According to the revised Guidelines for the prevention, diagnosis, care, and treatment of people with chronic hepatitis B infection, which were published in 2024, depending on the environment and eligibility requirements, about 50% of people with chronic hepatitis B infection are expected to need treatment. The majority of liver cancer patients in low-income environments are diagnosed late in the disease and pass away within months. Patients in high-income nations have access to surgery and chemotherapy, which can extend life by several months to a few years, and they arrive at the hospital earlier in the course of the illness. In technologically advanced nations, liver transplantation is occasionally performed on patients with cirrhosis or liver cancer, with different degrees of success [21]. Complete suppression of HBV DNA levels, disappearance of HBsAg, and seroconversion to anti-HBs antibodies following cessation of antiviral medication are the ultimate indicators of HBV eradication. Since HBsAg levels are surrogate markers for amounts of transcriptionally active covalently closed circular DNA (cccDNA), loss of HBsAg levels is crucial. If HBsAg is removed, the virus is probably inactivated. The majority of the HBsAg in chronic HBV patients who test negative for HBeAg is generated from integrated HBV DNA. The function of innate immunity cannot be overlooked, even while adaptive immunity is essential for managing and eradicating HBV infection. The innate immune system's cytokines and activation signals are essential for adaptive immunity [23].

Hepatitis C:

The Hepatitis C virus (HCV) is a single-stranded RNA virus that causes hepatitis C. HCV is mainly spread by direct bloodstream inoculation. It belongs to the Hepacivirus genus and Flaviviridae family. In most cases, HCV effectively eludes the immune system to produce chronic hepatitis, which, if left untreated, frequently results in severe fibrosis and cirrhosis. Although there are no effective immunizations to prevent HCV, the vast majority of cases of HCV can be quickly cured thanks to the development of direct-acting antivirals (DAA). Ambitious worldwide initiatives to eradicate HCV have resulted from this [15].

Types:

Acute:

It happens within the first six months following an HCV exposure. Although hepatitis C can be a transient condition, acute infections typically result in chronic infections [31].

Chronic:

It can be an infection that lasts a lifetime if neglected. More than half of HCV infections result in chronic infections [32,33].

Serious health issues include liver damage, cirrhosis (liver scarring), liver cancer, and even death can result from chronic hepatitis C [31].

Etiology:

The spherical, encapsulated, positive-strand ribonucleic acid (RNA) virus known as HCV has a diameter of about 55 nm. Although it belongs to

the family Flaviviridae, it is unique enough to be categorized as a distinct genus, Hepacivirus. The length of the genome is about 9.6 kb. At least ten proteins are produced from the polyprotein that it encodes. These comprise two proteins that are necessary for the generation of virions (p7 and NS2); three "structural" proteins, the nucleocapsid protein, core (C), and two envelope proteins (E1 and E2); and five nonstructural proteins that are crucial components of the viral replication complex (NS3, NS4A, NS4B, NS5A, and NS5B). Viral mutants, also referred to as "quasispecies," are produced as a result of the NS5B RNA polymerase's extremely high virion turnover and lack of proofreading [27].

Sign and symptoms:

It is rare for an acute HCV infection to cause symptoms, and when it does, most patients do not have any symptoms in the initial weeks following infection. The onset of symptoms can take anywhere from two weeks to six months. When symptoms do manifest, they could consist of:

Fever
Extreme exhaustion
Appetite loss
Nausea
Vomiting
Stomach discomfort
Black urine
Pale feces
Joint discomfort and jaundice (yellowing of the skin or eyes) [26].

Pathophysiology:

The virus does not directly damage hepatic cells to cause chronic hepatitis C. Instead, it is caused by an intermediate immune response that is strong enough to cause fibrosis and the death of liver cells but insufficient to completely eliminate the virus from its reservoirs. Quantitatively, CD4 and CD8 T-cell responses specific to the hepatitis C virus are lower during the chronic phase of infection compared to the acute phase. Individuals who have poor acute phase responses are more likely to develop chronic carriers than those who have adequate responses, and they are frequently asymptomatic (do not have jaundice). Qualitatively, effector function is compromised in HCV-specific CD8 T cells (both in lytic activity and antiviral cytokine secretion). The antiviral activity and restoration of a particular immunological response of the interferon and ribavirin combination likely account for its success [25].

Management:

Acute HCV infection either resolves on its own or develops into a chronic infection. The goal of treating chronic HCV infection is to achieve a sustained virologic response (SVR) in order to eradicate HCV RNA. After 12 weeks of treatment, SVR is attained when there is no longer any detectable HCV RNA in the blood, along with a decrease in antibody titers and improved liver histology. Injectable pegylated interferon and ribavirin were the cornerstones of treatment prior to the creation of the all-oral DAAs. This type of treatment not only had a 40% to 60% cure rate, but it also caused a number of side effects, such as flu-like illness, hematological side effects like thrombocytopenia and neutropenia, severe anemia, and neurocognitive side effects. With the introduction of DAAs, significant progress has been made in reducing treatment length from 48 weeks to 12 weeks, lowering side effects, raising cure rates to 90% to 97%, and doing away with injectable drugs.

At the moment, DAAs fall into three classes: NS3/4 serine proteases are blocked by second-generation protease inhibitors.

The NS5A inhibitors disrupt the structural protein NS5A, which is essential for the replication

complex's development. The NS5B polymerase inhibitor stops the enzyme that transcribes a negative-strand intermediate for subsequent viral offspring. To create a strong treatment plan against the diverse HCV genotypes, these three classes are combined in different ways [28,29,30]. Depending on the genotype, treatment history, and presence or absence of cirrhosis, the typical regimens range from 12 weeks to 24 weeks with or without ribavirin. The least responsive infection, Genotype 3, is linked to a higher risk of hepatocellular carcinoma and a fast accelerated progression of fibrosis with the existing DAAs. The most prevalent genotype in the US, genotype 1, has four approved therapies, two of which simply call for a single daily medication [30]

Hepatitis D:

The Hepatitis D virus (HDV) is a single-stranded, enclosed RNA molecule that causes hepatitis D. Since HDV is totally dependent on HBV for its life cycle, it is sometimes categorized as a subvirus. HDV is the smallest virus known to infect humans. Similar to HBV, transmission can happen concurrently with an HBV infection (a condition known as coinfection) or in patients who have a persistent HBV infection (a condition known as superinfection). The natural history of HDV infection is determined by this relationship to the date of HBV infection; superinfection more frequently results in a rapid clinical deterioration with progressive hepatitis, cirrhosis, and the development of cirrhosis complications, including HCC [15].

Types:

Coinfection:

Acute hepatitis B and acute hepatitis D occur when a susceptible person contracts both HBV and HDV at the same time [42].

Superinfection:

When HDV infects people who have a persistent HBV infection, the clinical manifestation and course of hepatitis D are different (superinfection pattern) [42].

Etiology:

HDV infection is spread parenterally and results in both acute and chronic inflammatory liver damage. While intravenous drug use is typically the cause in industrialized countries, poor sterilization procedures are the cause in settings with low resources. Intravenous drug usage and blood transfusions are risk factors [45]. Infection is classified as either superinfection (HDV infection in a person with chronic hepatitis B) or coinfection (acute simultaneous infection with HDV and HBV) [46].

Sign and Symptoms:

When HBV and HDV infections occur together, it can cause mild-to-severe hepatitis with symptoms that are similar to those of other acute viral hepatitis infections. These symptoms, which include fever, exhaustion, appetite loss, nausea, vomiting, dark urine, pale-colored feces, jaundice (yellow eyes), and even fulminant hepatitis, usually manifest three to seven weeks after the first infection. Nonetheless, recovery is typically full, fulminant hepatitis seldom develops, and chronic hepatitis D rarely develops (less than 5% of acute hepatitis). A person who already has a chronic HBV infection may get HDV in a superinfection. across 70–90% of people with chronic hepatitis B, superinfection with HDV promotes the disease's progression to a more severe state across all age groups. Compared to people with HBV mono-infection, HDV superinfection significantly speeds up the development of cirrhosis. Hepatocellular carcinoma (HCC) is more common in patients with HDV-induced cirrhosis; nevertheless, it is still unknown how HDV

produces more severe hepatitis and a quicker progression of fibrosis than HBV alone [41].

Pathophysiology:

HDV is structurally composed of a lipoprotein envelope from HBV, a ribonucleic acid (RNA) genome, and hepatitis D antigen (HDAg). The HDAg is the single gene encoded by the genome. HDAg comes in two varieties, long and short, which are named by their respective sizes. Hepatocytes are the site of viral replication. The virus is distinct in that it transcribes its messenger RNA using host RNA polymerase II. While lengthy HDAg proteins control viral assembly and prevent viral replication, small HDAg proteins directly attach to HDV RNA to initiate viral replication. Once the HBV envelope is included, the virus is fully formed and then released.

HBV is necessary for HDV infection to occur. Acute HBV and HDV infection occur when a person is sensitive to HBV is coinfected with both viruses. With the exception of a biphasic course with two peaks in serum alanine aminotransferase levels that occur several weeks apart, coinfection clinically resembles typical acute HBV. Before HDV replication can start during acute coinfection, HBV infection must be established. Coinfection carries a higher risk of liver failure and may be more severe than HBV monoinfection. About 5% of patients develop chronic infection, which is defined as persistence of infection for more than six months. The majority of patients recover during acute coinfection with HBV and HDV. A superinfection, which can manifest as severe acute hepatitis or a worsening of preexisting chronic HBV, can happen in people who are chronic carriers of HBsAg. Acute HDV infection can be misinterpreted for an HBV flare-up in patients with chronic HBV infection. If HDV superinfection is not taken into account, the clinical presentation and preliminary tests in individuals with undiagnosed HBV infection may be misinterpreted as acute HBV infection. Compared to HBV/HDV coinfection, superinfection frequently has a more severe clinical course. Ninety percent of these patients develop chronic HDV because HBsAg permits ongoing viral replication. Compared to chronic HBV infection, chronic HDV infection results in more serious morbidity (cirrhosis, hepatocellular cancer, increasing fibrosis, and hepatic decompensation) [47].

Management:

Pegylated or conventional interferon alpha therapy are currently recognized therapies for chronic hepatitis D [34]. Research indicates that pegylated interferon alpha is useful in lowering the viral load and the disease's effects while the medication is being administered, but the benefits usually end if the medication is stopped [35]. There have been reports of late relapse following therapy, and the effectiveness of this treatment often does not exceed 20% [36,37]. The European Medicines Agency's Committee for Medicinal Products for Human Use authorized the antiviral medication Hepcludex (bulevirtide) in May 2020 to treat hepatitis D [38]. Bulevirtide prevents the hepatitis B and D viruses from entering hepatocytes by binding to and deactivating the sodium/bile acid cotransporter[39,40]. Since bulevirtide and pegylated interferon alpha are believed to have a synergistic effect that increases therapy response rates, they may be administered together. Bulevirtide was a safe, well-tolerated medication for individuals with HDV-related compensated cirrhosis and clinically severe portal hypertension. It significantly improved biochemical indicators and increased liver function measures. Pegylated interferon lambda (λ), which binds to hepatocyte surface receptors and initiates an intracellular signaling cascade via the JAK-STAT signaling pathway and activates anti-viral cell-mediated immunity, is one of the several hepatitis D

therapies now being developed. By preventing the farnesylation of the L-HDAg, the prenylation inhibitor lonafarnib stops the formation of hepatitis D virus particles [43]. A nucleic acid polymer called REP2139-Ca inhibits the release of hepatitis B surface antigen, which is necessary for the formation of hepatitis D virus particles [44].

Hepatitis E:

The Hepatitis E virus (HEV), a single-stranded, nearly enclosed RNA molecule belonging to the Hepeviridae family, is the cause of hepatitis E infection. Eight genotypes are known, with the most researched being genotypes 1-4. Either the fecal-oral route (genotypes 1 and 2) or zoonotic transmission by consumption of raw or undercooked meat (genotypes 3 and 4) is the mode of transmission. Though incidences of chronic hepatitis E have been documented in immunocompromised hosts, HEV usually causes an acute, self-limited hepatitis that is especially severe in pregnant women. Improving cleanliness and immunization are the mainstays of prevention, while a vaccine is only available in China. Acute HEV is currently treated with supportive care, whereas chronic HEV is treated with a multimodal strategy that includes reducing underlying immunosuppression and sometimes ribavirin [15].

Etiology:

HEV is a single-stranded, nonenveloped, icosahedral ribonucleic acid virus that has a diameter of roughly 27 to 34 nm. There are four known genotypes of HEV: 1 through 4.

Genotypes 1&2:

These genotypes are human viruses that are mostly present in impoverished nations, such as parts of Africa, Asia, Central America, and the Middle East. They are spread by polluted water through the fecal-oral route. These genotypes usually afflict young adults (15–40 years old) during outbreaks, resulting in a self-limited acute infection that often does not develop into a chronic illness. However, acute infections can be severe and cause fulminant liver failure in patients who are pregnant or have chronic liver disease [48].

Genotypes 3&4:

These genotypes are mostly zoonotic; they are present in animals and are spread to people by eating undercooked meat, such deer and pig. Developed nations including the US, Australia, Japan, and China have higher rates of these genotypes.They mostly affect adults over 40 and typically cause occasional cases. Although they can result in acute infections, there is a chance that they could develop into chronic infections, especially in people with impaired immune systems, such as those receiving immunosuppressive medications for solid organ transplants or those infected with the human immunosuppressive virus [48,49].

Sign and Symptoms:

Anorexia, malaise, nausea and vomiting, fever, and jaundice are typical signs of viral hepatitis.
Pregnant women are particularly at risk for fulminant hepatitis and death from hepatitis E [52].

Pathophysiology:

Large-scale waterborne epidemics, especially in developing nations, are frequently caused by HEV, which is mostly spread through the fecal-oral route via contaminated water. Although it is uncommon, HEV can also be a zoonotic infection spread by feces. Although person-to-person transmission is rare, blood transfusions can spread HEV, particularly in endemic regions.Vertical transmission of HEV from infected mothers to their offspring has the potential to cause serious fetal loss and neonatal mortality.Although there is not enough information on HEV transmission through breast milk, the virus has been isolated in breast milk and serum titers have been found to be similar. HEV infections have an incubation period

of 28 to 40 days. Following ingestion, the virus enters the portal circulation through the gastrointestinal mucosa and eventually travels to the liver. Heparan sulfate is probably the mechanism by which the HEV virion binds to its receptor in the liver. Clathrin-mediated endocytosis, viral uncoating, and ribonucleic acid release occur after this first binding [50].

Mnagement:

In most cases, acute HEV infections resolve on their own and just need supportive care. After symptoms appear, abnormal biochemical markers usually go away in one to six weeks. On the other hand, those who experience fulminant liver failure can need a liver transplant. It is yet unclear how antiviral medications like ribavirin can treat acute HEV infection in persons with impaired immune systems. Pregnant women with acute HEV infection should not take ribavirin because of its teratogenic risk. Thus, during treatment and for six months following therapy, women of reproductive age and males who have sex with women of childbearing age should get contraception counseling. Although resistance mutations may lessen efficiency, ribavirin has demonstrated a good sustained virological response for chronic HEV infection. Modifying immunosuppressive therapy and employing antiviral medications such ribavirin, peginterferon, or both should be taken into consideration for patients with chronic HEV who are immunocompromised. Animal research suggests that calcineurin inhibitors and mammalian target of rapamycin (mTOR) inhibitors may promote HEV replication, while mycophenolate mofetil seems to be a safer substitute. Therefore, although there are no set recommendations, lowering the tacrolimus dosage and maximizing immunosuppression by raising mycophenolate mofetil or corticosteroids may be a sensible strategy. Antiretroviral therapy-induced immune reconstitution may eliminate HEV viremia in HIV patients with chronic hepatitis E; if this is not successful, ribavirin may be considered as an additional treatment [51].

CONCLUSION

Despite significant advancements in knowledge, diagnosis, prevention, and treatment, viral hepatitis continues to pose a serious threat to worldwide public health. Scientific advancements have greatly decreased the morbidity and death linked to these illnesses, from early accounts of jaundice to contemporary molecular characterization of hepatitis viruses. Hepatitis B, C, and D are more dangerous because they can result in chronic infection and long-term consequences such cirrhosis, hepatocellular cancer, and liver failure, while hepatitis A and E are mostly acute, self-limiting disorders intimately related to sanitation and hygiene. The prevalence of hepatitis A and B has significantly decreased in many areas due to the availability of effective vaccines, underscoring the need of prevention as a key component of control measures. On the other hand, the lack of a hepatitis C vaccine highlights the significance of early detection and antiviral treatment. The development of direct-acting antivirals has transformed the treatment of hepatitis C, resulting in high cure rates with shorter treatment times and fewer side effects. In a similar vein, new medicines for hepatitis D and growing therapeutic choices for hepatitis B provide hope for better disease control and better results. However, there are still a lot of obstacles to overcome, especially in low- and middle-income nations where access to diagnosis, immunization, and treatment is restricted. The necessity for widespread awareness, reliable surveillance systems, and fair access to healthcare is further highlighted by globalization, migration, and shifting epidemiological patterns. To lessen the worldwide burden of viral hepatitis and eventually work toward its eradication, ongoing research into

viral pathophysiology, vaccine development, and innovative antiviral treatments is crucial, along with public health initiatives and education.

REFERENCES

1. Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World Journal of Gastroenterology [Internet]. 2022 Apr 14;28(14):1405–29. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048475/
2. Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From Hepatitis a to E: a Critical Review of Viral Hepatitis. World Journal of Gastroenterology. 2021 Apr 28;27(16):1691–715.
3. Ringehan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philosophical Transactions of the Royal Society B: Biological Sciences [Internet]. 2017 Sep 11;372(1732):20160274. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597741/
4. Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. The National medical journal of India [Internet]. 2006 Jul 1;19(4):203–17. Available from: https://europepmc.org/article/med/17100109
5. History of viral hepatitis - ProQuest [Internet]. Proquest.com. 2026 [cited 2026 Feb 23]. Available from: https://www.proquest.com/openview/9d8d4160420b3c9d1746fc75783878d2/1?pq-origsite=gscholar&cbl=1796426
6. Martin NA. The Discovery Of Viral Hepatitis: A Military Perspective. Journal of the Royal Army Medical Corps. 2003 Jun 1;149(2):121–4.
7. Alter MJ, Mast EE. THE EPIDEMIOLOGY OF VIRAL HEPATITIS IN THE UNITED STATES. Gastroenterology Clinics of North America. 1994 Sep;23(3):437–55.
8. Artinspiring. Hepatitis viruses set. Structure of hepatitis A, B, C, D, E viruses with parts [Internet]. Dreamstime. 2022 [cited 2026 Feb 23]. Available from: https://www.dreamstime.com/hepatitis-viruses-set-structure-b-c-d-e-parts-descriptions-liver-failure-disease-flat-vector-illustration-image257316174
9. González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World Journal of Gastroenterology [Internet]. 2016 Jan 28;22(4):1421–32. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26819511
10. Simmonds P. Variability of hepatitis C virus. Hepatology [Internet]. 1995 Feb [cited 2019 Jun 26];21(2):570–83. Available from: https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.1840210243
11. Lemon SM, Thomas DL. Vaccines to Prevent Viral Hepatitis. Wood AJJ, editor. New England Journal of Medicine. 1997 Jan 16;336(3):196–204.
12. Koziel MJ, Peters MG. Viral Hepatitis in HIV Infection. New England Journal of Medicine. 2007 Apr 5;356(14):1445–54.
13. Mehta P, Reddivari AKR. Viral Hepatitis [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554549/
14. Wikipedia Contributors. Hepatitis A [Internet]. Wikipedia. Wikimedia Foundation; 2019. Available from: https://en.wikipedia.org/wiki/Hepatitis_A
15. Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World Journal of Gastroenterology [Internet]. 2022 Apr 14;28(14):1405–29. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048475/

16. World Health Organization. Hepatitis A [Internet]. World Health Organization. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a
17. Vishnu Girish, Grant LM, John S. Hepatitis A [Internet]. Nih.gov. StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459290/#article-22785.s3
18. Iorio N, John S. Hepatitis A [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459290/#article-22785.s5
19. Vishnu Girish, Grant LM, John S. Hepatitis A [Internet]. Nih.gov. StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459290/#article-22785.s9
20. Bharucha DV. Hepatitis A: Symptoms, Causes, Treatment & More | PharmEasy [Internet]. PharmEasy Blog. 2025 [cited 2026 Feb 23]. Available from: https://pharmeasy.in/blog/vaccine-what-is-hepatitis-a-causes-symptoms-and-how-it-spreads/
21. WHO. Hepatitis B [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
22. Lee WM. Hepatitis B Virus Infection. New England Journal of Medicine. 1997 Dec 11;337(24):1733–45.
23. Checking your browser - reCAPTCHA [Internet]. Nih.gov. 2024 [cited 2026 Feb 23]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11125943/#sec4-viruses-16-00724
24. Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World journal of gastroenterology [Internet]. 2007;13(1):82–90. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17206757
25. Poynard T, Yuen MF, Ratzin V, Lai CL. Viral hepatitis C. The Lancet [Internet]. 2003 Dec 20 [cited 2020 Mar 1];362(9401):2095–100. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)15109-4/fulltext
26. World Health Organization. Hepatitis C [Internet]. World Health Organization. World Health Organization: WHO; 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
27. Securly - Geolocation sharing [Internet]. Nih.gov. 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430897/#article-22791.s3
28. Oraby M, Khorshed A, Abdul-Rahman E, Ali R, Elsutohy MM. A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine. Journal of Pharmaceutical and Biomedical Analysis. 2019 Jul;171:104–10.
29. Cunningham HE, Shea TC, Grgic T, Lachiewicz AM. Successful treatment of hepatitis C virus infection with direct-acting antivirals during hematopoietic cell transplant. Transplant Infectious Disease. 2019 Apr 11;21(3).
30. Basit H, Tyagi I, Janak Koirala. Hepatitis C [Internet]. Nih.gov. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430897/#article-22791.s8
31. CDC. Clinical Overview of Hepatitis C [Internet]. Hepatitis C. 2024. Available from: https://www.cdc.gov/hepatitis-c/hcp/clinical-overview/index.html
32. Thomas DL, Seeff LB. Natural History of Hepatitis C. Clinics in Liver Disease. 2005 Aug;9(3):383–98.

33. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C. Annals of Internal Medicine [Internet]. 2000 Feb 15;132(4):296. Available from: https://annals.org/aim/fullarticle/1309488/pathogenesis-natural-history-treatment-prevention-hepatitis-c
34. Yurdaydin C, Idilman R. Therapy of Delta Hepatitis. Cold Spring Harbor Perspectives in Medicine. 2015 Aug 7;5(10):a021543.
35. Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database of Systematic Reviews. 2011 Dec 7;
36. Heidrich B, Cihan Yurdaydin, Gökhan Kabaçam, Ratsch BA, Kalliopi Zachou, Bremer B, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. 2014 Jul 1;60(1):87–97.
37. Pascarella S, Negro F. Hepatitis D virus: an update. Liver International. 2010 Sep 29;31(1):7–21.
38. Hepcludex | European Medicines Agency (EMA) [Internet]. European Medicines Agency (EMA). 2020 [cited 2026 Feb 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex#authorisation-details-section
39. FRANCISCO EM. Hepcludex: Pending EC decision - European Medicines Agency [Internet]. European Medicines Agency. 2020 [cited 2026 Feb 23]. Available from: https://web.archive.org/web/20200615185201/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/hepcludex
40. Bulevirtide - MYR Pharma - AdisInsight [Internet]. Springer.com. 2025 [cited 2026 Feb 23]. Available from: https://adisinsight.springer.com/drugs/800031990
41. World Health Organization. Hepatitis D [Internet]. Who.int. World Health Organization: WHO; 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-d
42. Farci P, Niro G. Clinical Features of Hepatitis D. Seminars in Liver Disease. 2012 Aug;32(03):228–36.
43. Koh C, Canini L, Harel Dahari, Zhao X, Uprichard SL, V. Haynes-Williams, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infectious Diseases. 2015 Oct 1;15(10):1167–74.
44. Vaillant A. REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection. ACS Infectious Diseases. 2018 Sep 10;5(5):675–87.
45. Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011–2016 | 10.1093/cid/ciz001_Sci-hub [Internet]. Pismin.com. 2016 [cited 2026 Feb 23]. Available from: https://www.pismin.com/10.1093/cid/ciz001
46. Sachdeva K, Vishnu Girish, John S. Hepatitis D [Internet]. Nih.gov. StatPearls Publishing; 2025 [cited 2026 Feb 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470436/#article-22792.s3
47. Masood U, John S. Hepatitis D [Internet]. Nih.gov. StatPearls Publishing; 2022 [cited 2025 Aug 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470436/#article-22792.s5
48. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. New England Journal of Medicine. 2012 Sep 27;367(13):1237–44.
49. Vishnu Girish, Grant LM, Sharma B, Janak Koirala. Hepatitis E [Internet]. Nih.gov. StatPearls Publishing; 2025 [cited 2026 Feb

23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532278/#article-22793.s3

50. Vishnu Girish, Grant LM, Sharma B, Janak Koirala. Hepatitis E [Internet]. Nih.gov. StatPearls Publishing; 2025 [cited 2026 Feb 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532278/#article-22793.s5
51. Vishnu Girish, Grant LM, Sharma B, Janak Koirala. Hepatitis E [Internet]. Nih.gov. StatPearls Publishing; 2025 [cited 2026 Feb 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532278/#article-22793.s9
52. Hepatitis E - Hepatic and Biliary Disorders [Internet]. Merck Manuals Professional Edition. Available from: https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/hepatitis/hepatitis-e

HOW TO CITE: Sakshi Shinde, Ankita Darekar, Dr. Ashok Giri, General Current Perspectives on All Hepatitis Viruses- A Comprehensive Review, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 3, 128--142. https://doi.org/10.5281/zenodo.18851058